Inhibition of CYP17A1 and CYP19A1 activities by curcuminoids indicate similar molecular entities or modified compounds based on core structures of curcuminoids could be explored as potential treatments for prostate cancer by targeting CYP17A1 and for breast cancer by targeting CYP19A1. This evidence concerns the gene CYP17A1 and breast cancer.